Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferatoractivated receptor in PC-3 cells

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 81-90

  Zhu, Hai ^a,b   Pan, Xiaojing ^d   Qi, Haiyan ^b   Wang, Xuechun ^c   Hou, Sichuan ^b   Han, Baojian ^e   Liu, Zhijun ^b   Xu, Luo ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b Department of Urology ^*  (China)

^c Municipal Hospital   (China)

^d Affiliated Hospital of Medical College   (China)

^e Eighth People's Hospital of Qingdao City   (China)

Author keywords

Akt; Apoptosis; ERK1; PI3K; Prostate cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; TROGLITAZONE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMANS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; PPAR GAMMA; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 78650732476     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001045     Document Type: Article

References (54)

1. Willson TM, Lambert MH and Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70: 341-367, 2001.
2. Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature 405: 421-424, 2000.
3. Kim KY, Kim SS and Cheon HG: Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gammaagonists in MCF-7 breast cancer cells. Biochemical Pharmacol 72: 530-540, 2006
4. Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H and Mori M: A ligand for peroxisome activated receptor Á inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50: 563-567, 2002
5. Chaffer CL, Thomas DM, Thompson EW and Williams ED: PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6: 53, 2006
6. Elnemr A, Ohta T, Iwata K, et al: PPARÁ ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 17: 1157-1164, 2000
7. Sato H, Ishihara S, Kawashima K, et al: Expression of proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonist. Br J Cancer 83:1394-1400, 2000
8. Berger J, Bailey P, Biswas C, et al: Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137: 4189-4195, 1996
9. Koga H, Sakisaka S, Harada M, et al: Involvement of p21 (WAF1/Cip1), p27 (Kip1), and p18 (INK4c) in troglitazone induced cell-cycle arrest in human hepatoma cell lines.Hepatology 33: 1087-1097, 2001
10. Yin F, Wakino S, Liu Z, et al: Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell-cycle regulators. Biochem Biophys Res Commun 286: 916-922, 2001
11. Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352, 1998
12. Mueller E, Smith M, Sarraf P, et al: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97: 10990-10995, 2000
13. Matsuyama M and Yoshimura R: Peroxisome proliferatoractivated receptor-Á is a potent target for prevention and treatment in human prostate and testicular cancer. PPAR Res 2008: 249849, 2008
14. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW and Chen CS: Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functionsindependently of PPARgamma. Cancer Res 65: 1561-1569, 2005
15. Gschwind A, Fischer OM and Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361-370, 2004 (Pubitemid 38579482)
16. Mckeehan WL, Adams PS and Rosser MP: Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pityitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 44: 1988-2010, 1984
17. Thomson AA, Foster BA and Cunha GR: Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. Development 124: 2431-2439, 1997
18. Gibbs JB: Mechanism-based target identification and drug discovery in cancer research. Science 287: 1969-1973, 2000
19. 19. Gibbs JB: Anticancer drugs targets: growth factors and growth factors signaling. J Clin Invest 105: 9-13, 2000
20. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985
21. Wetzker R and Bohmer FD: Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4: 651-657, 2003
22. Carpenter G: Employment of the epidermal growth factor receptor in growth factor independent signaling pathways. J Cell Biol 146: 697-702, 1999
23. Yan Y, Shirakabe K and Werb Z: The metalloprotease kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 158: 221-226, 2002
24. Garner OS, Dewar BJ, Earp HS, Samet JM and Graves LM: Dependence of peroxisome proliferatoractivated receptor ligandinduced mitogen-activated protein kinase signaling on epidermal growth factor transactivation. J Biol Chem 278: 46261-46269, 2003.
25. Shah BH, Farshori MP, Jambusaria A and Catt KJ: Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation. J Biol Chem 278: 19118-19126, 2003.
26. Shah BH, Soh JW and Catt KJ: Dependence of gonadotropinreleasing hormone induced neuronal MAPK signaling on epidermal growth factor receptor transactivation. J Biol Chem 278: 2866-2875, 2003
27. Qi W and Martinez JD: Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res 160: 217-223, 2003.
28. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi CA: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991
29. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
30. Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137, 2001
31. Chen D, Xu LG, Chen L, Li L, Zhai Z and Shu HB: NIK is component of the EGF/heregulin receptor signaling complexes. Oncogene 22: 4348-4355, 2003.
32. Habib AA, Chatterjee S, Park SK, Ratan RR, Lefebvre S and Vartanian T: The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptortyrosine kinase signalosome. J Biol Chem 276: 8865-8874, 2001
33. Romashkova JA and Makarov SS: NF-kappaB is target of AKT in anti-apoptotic PDGF signaling. Nature 401: 86-90, 1999]
34. Gong L, Li Y, Nedeljkovic-Kurepa A and Sarkar FH: Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22: 4702-4709, 2003
35. Doepfner KT, Spertini O and Arcaro A: Autocrine insulinlike growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/ Akt pathway. Leukemia 21: 1921-1930, 2007
36. Gronberg H: Prostate cancer epidemiology. Lancet 361: 859-864, 2003
37. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics. CA Cancer J Clin 54: 8-29, 2004.
38. Clay CE, Monjazeb A, Thorburn J, Chilton FH and High KP: 15-Deoxydelta12, 14-prostaglandin J2-induced apoptosis does not require PPAR gamma in breast cancer cells. J Lipid Res 43: 1818-1828, 2002
39. Rumi MA, Ishihara S, Kadowaki Y, et al: Peroxisome proliferator-activated receptor gamma-dependent and -independent growth inhibition of gastrointestinal tumour cells. Genes Cells 9: 1113-1123, 2004
40. Yoshida K, Tanabe K, Fujii D, Oue N, Yasui W and Toge T: Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptorgamma in gastric carcinoma cells. Anticancer Res 23: 267-273, 2003
41. Baek SJ, Wilson LC, His LC and Eling TE: Troglitazone,a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 278: 5845-5853, 2003
42. Papageorgiou E, Pitulis N, Msaouel P, Lembessis P and Koutsilieris M: The non-genomic crosstalk between PPARgamma ligands and ERK1/2 in cancer cell lines. Expert Opin Ther Targets 11: 1071-1085, 2007
43. Laidler P, Dulinska J and Mrozicki S: Does the inhibition of c-myc expression mediate the antitumor activity of PPAR' ligands in prostate cancer cell lines? Arch Biochem Biophys 462: 1-12, 2007.
44. Pérez-Ortiz JM, Tranque P, Vaquero CF, et al: Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 279: 8976-8985, 2004.
45. Pérez-Ortiz JM, Tranque P, Vaquero CF, et al: Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 279: 8976-8985, 2004
46. Bruemmer D, Yin F, Liu J, et al: Regulation of the growth arrest and DNA damage-inducible gene 45(GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ Res 93: 38-47, 2003
47. Farrow B and Evers BM: Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 301: 50-53, 2003
48. Papageorgiou E, Pitulis N, Manoussakis M, Lembessis P and Koutsilieris M: Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med 14: 403-411, 2008.
49. Ciardiello F and Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39: 1348-1354, 2003.
50. Dancey JE and Freidlin B: Targeting epidermal growth factor receptor-are we missing the mark? Lancet 362: 62-64, 2003.
51. Huang SM, Li J and Harari PM: Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 1: 507-514, 2002.
52. Chott A, Sun Z, Morganstern D, et al: Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155: 1271-1279, 1999.
53. Li X, Yang X, Xu Y, Jiang X, Li X, Nan F and Tang H: Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma. Cell Res 19: 720-732, 2009
54. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gélinas C and Rabson AB: Mechanisms of constitutive NFkappaB activation in human prostate cancer cells. Prostate 52: 183-200, 2002.